Study Design by Therapeutic Modality in Shared Preclinical Models
The pain and neurology pipeline comprises several distinct therapeutic modalities. A neuropathic pain program today may be a small molecule sodium...
Histological Markers of Myelination in Demyelination Studies
Remyelination trials in multiple sclerosis are judged on imaging and functional endpoints because myelin cannot be examined directly in a patient. A...
Pain Endpoints in Collagen-Induced and Antibody-Induced Arthritis
Pain is a principal presenting symptom of rheumatoid arthritis, and persistent pain despite low inflammatory activity is now the subject of its own...
Preclinical Evidence Requirements for a Non-Opioid Analgesic
The clinical value of a non-opioid analgesic is defined relative to the established agents it is intended to replace, so its preclinical evaluation...
Cuprizone and EAE Models of Demyelination: Mechanism and Application
Multiple sclerosis therapy has been transformed by agents that control inflammation, and the unmet need has shifted toward repair. Remyelination has...
Non-Opioid Analgesic Mechanisms and Their Preclinical Pain Models
The FDA issued draft guidance on the development of non-opioid analgesics for acute pain in 2022, covering development programs, labeling claims and...
Diabetic Wound Healing in the GLP-1 Era: What Systemic Metabolic Control Does Not Solve
The GLP-1 receptor agonists have changed the trajectory of type 2 diabetes care, and the evidence now suggests their reach extends to the diabetic...
Five Days From a Single Injection: What Long-Acting Local Anesthetics Have to Prove in the Pig
Postoperative pain management is in the middle of a reimbursement shift. Since January 2025, Medicare has paid separately for qualifying non-opioid...
Preclinical Models of Diabetic Neuropathy: STZ, High Fat Diet, and the ZDF Rat
Diabetic peripheral neuropathy affects nearly half of people living with diabetes, and it remains one of the harder complications to treat. The...